rhuFab V2 (ranibizumab)

DRUG6 trials

Sponsors

Genentech, Inc.

Conditions

Age-Related MaculopathyAge-related Macular DegenerationChoroidal NeovascularizationMacular Degeneration

Phase 1

Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)

CompletedNCT00056823

Genentech, Inc.Age-Related Maculopathy

Start: 2003-03-31End: 2005-12-31Target: 168Updated: 2013-06-21

Phase 3

A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration

CompletedNCT00056836

Genentech, Inc.Macular Degeneration

Start: 2003-03-31End: 2005-12-31Target: 720Updated: 2014-05-16

A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration

CompletedNCT00061594

Genentech, Inc.Macular Degeneration

Start: 2003-05-31End: 2006-09-30Target: 426Updated: 2014-03-19

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

CompletedNCT00090623

Genentech, Inc.Macular Degeneration

Start: 2004-08-31End: 2007-03-31Target: 180Updated: 2013-06-21

Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)

CompletedNCT00095433

Genentech, Inc.Macular Degeneration

Start: 2002-09-30End: 2006-08-31Target: 100Updated: 2014-03-26

A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

CompletedNCT00251459

Genentech, Inc.Age-related Macular Degeneration, Choroidal Neovascularization

Start: 2005-11-30End: 2007-09-30Target: 5000Updated: 2014-03-10

Related Papers

Prevalence of Macular Atrophy in the MARINA Study of Ranibizumab versus Sham for Neovascular Age-Related Macular Degeneration.

2023-04-2211 citations

Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report

British Journal of Ophthalmology2021-09-136 citations

Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.

2014-01-1172 citations

Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach.

2013-03-05149 citations

Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials.

2013-02-2810 citations

A new epidemiological aid in deciding whether to continue or stop a treatment.

2012-07-011 citations

Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.

2009-01-0167 citations

Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.

2007-11-01159 citations

Ranibizumab for neovascular age-related macular degeneration.

2006-10-014033 citations

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

2006-10-012471 citations